Fujian Cancer Hospital

This study is testing whether adding the drug dalpiciclib to standard hormone therapy can help prevent breast cancer from coming back in women with early-stage HR+/HER2- breast cancer. About 2,000 women will receive either a higher dose for 2 years or a lower dose for 3 years, al…

This phase 2 trial is testing a combination of two drugs, Sacituzumab tirumotecan and QL1706, in 89 women with recurrent or metastatic cervical cancer that cannot be treated with surgery or radiation. The goal is to see if the combo can shrink tumors and improve survival. Partici…

This Phase 3 trial tests whether adding a chemotherapy drug (capecitabine) to a standard two-drug regimen (dalpiciclib plus hormone therapy) can slow cancer growth longer in people with HR+/HER2- breast cancer that has spread to internal organs. About 258 participants will be ran…

This phase 2 trial is testing whether a short course of radiation followed by two cycles of chemotherapy (CAPOX) plus an experimental immunotherapy drug (QL1706) can help people with rectal cancer that has spread to the liver. The study will enroll 42 adults aged 18-75 who have n…

This study tests whether adding radiotherapy to immunotherapy after surgery can help people with a certain type of advanced lung cancer (stage III N2 non-small cell lung cancer) live longer without the cancer coming back. About 60 adults aged 18 to 75 who have had surgery and hav…

This phase 2 trial is testing whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy before surgery can help shrink tumors in people with locally advanced cervical cancer. The study will enroll 43 participants and measure ho…